Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Quotient Clinical upgrades Nottingham clinical facilities
The expanded facility’s bed capacity has been increased by 50%. The facility houses a sample processing laboratory for human ADME studies. The UK regulatory authority – the Medicines
The expanded facility’s bed capacity has been increased by 50%. The facility houses a sample processing laboratory for human ADME studies. The UK regulatory authority – the Medicines
Burkert and BBS said QuickCONNECT offers short sterilisation times, lower water consumption and higher product yields leading to improved process returns. The BBS Sterile QuickCONNECT System employs standard
As a result of this, SBIO can now independently drive the development of its lead JAK2 program. Recent data from phase 2 clinical trials of SB1518 indicated promising
The ‘301 patent is directed to identifying small molecules that are affected by using metabolomics. It provides a method to evaluate chemical agents for drug effects and toxicity,
The filing was based on positive test results with respect to specific chemical agents that improved the delivery of active ingredients when used in conjunction with the company’s
Lingelbach has succeeded Gerd Zettlmeissl, who is resigning from the company to pursue other personal and professional interests. Lingelbach has held leading positions of increasing international responsibility at
The trial is intended to establish if Multikine administered prior to current standard of care (surgery plus radiotherapy or surgery plus concurrent chemo radiotherapy) in previously untreated subjects
The MAA includes clinical and safety data from Savient‘s pivotal Phase 3 studies and the Open Label Extension program of Krystexxa. Savient Pharma CEO John Johnson said they
Thermo Fisher will refurbish all traded-in instruments and donate them to Seeding Labs, an organization that places scientific instrumentation in the academic institutions of developing nations. Thermo Fisher
For the first quarter of 2011, the company has reported a net loss of $12.36m, or $0.17 loss per diluted share, compared to $8.18m or $0.13 per diluted